RCWM
LCTX icon

Red Crane Wealth Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Red Crane Wealth Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$782K Hold
597,263
– – 0.58% 42
2026
Q1 		$944K Hold
597,263
– – 0.78% 34
2025
Q4 		$997K Buy
597,263
+85,900
+17% +$149K 0.82% 34
2025
Q3 		$864K Buy
511,363
+15,365
+3% +$18.2K 0.73% 34
2025
Q2 		$450K Buy
495,998
+2
+0% +$1 0.41% 43
2025
Q1 		$224K Buy
495,996
+155,760
+46% +$91.4K 0.21% 61
2024
Q4 		$171K Buy
+340,236
New +$250K 0.16% 64

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Red Crane Wealth Management's LCTX Position: Q2 2026 in Review

Red Crane Wealth Management held its Lineage Cell Therapeutics (LCTX) position steady in Q2 2026 at 597,263 shares worth $782K. The position accounts for 0.58% of the portfolio, ranked #42.

Red Crane Wealth Management first reported a position in LCTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $997K in Q4 2025. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Red Crane Wealth Management held 597,263 shares of Lineage Cell Therapeutics worth $782K as of Q2 2026.
  • Red Crane Wealth Management left its Lineage Cell Therapeutics share count unchanged in Q2 2026.
  • Lineage Cell Therapeutics made up 0.58% of Red Crane Wealth Management's portfolio in Q2 2026, its #42 holding.
  • Red Crane Wealth Management first reported a position in Lineage Cell Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Red Crane Wealth Management's Lineage Cell Therapeutics position peaked at $997K in Q4 2025.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Red Crane Wealth Management's 13F filing for Q2 2026, filed 29 Jul 2026.